Navigation Links
VIVUS Provides Regulatory Update on QNEXA
Date:9/15/2011

uct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officerbkorb@troutgroup.com 650-934-5200646-378-2923
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
2. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
3. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
4. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
5. VIVUS to Present at Three Upcoming Investor Conferences in March
6. VIVUS Provides Regulatory Update on QNEXA NDA
7. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
8. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
9. VIVUS to Present at Two Upcoming Investor Conferences
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 A hernia is condition ... protrudes through the wall of a weak muscle area. Obesity, ... are some of the causes of hernias. There are several ... incisional. An inguinal hernia is when part of the abdominal ... found in the area of the umbilicus. A hiatal hernia ...
(Date:11/26/2014)... 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical company ... infectious diseases, announced today the addition of ... opinion leader in the areas of pneumonia and ... Founder and Chief Executive Officer, Vu ... extensive experience investigating bacterial toxins and key mechanisms ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... NovaRx Corporation announced today the appointment of Norrie ... Chief Operating Officer. Dr. Russell brings to the ... and a long history of success driving innovation in ... leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) ... milestones,achieved in 2008 and preview objectives for 2009 during ... New York City today. , David Smoller, ... discuss the progress and expected potential of the,two companies, ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6
(Date:11/27/2014)... Los Angeles, CA (PRWEB) November 27, 2014 ... are thrilled to be part of Omadox, a feature ... Film Festival, including an award for best ensemble cast. It ... Festival. This is a great start to a successful cinematic ... experimental/sci-fi, black and white movies. If you enjoy experimental mystery, ...
(Date:11/27/2014)... Acapulco, Guerrero (PRWEB) November 27, 2014 ... the time individuals allot to sleep has lessened, ... televisions and laptops, the quality of sleep has ... workers falls asleep on the job (Reference: ... American worker’s productivity index by an incalculable amount, ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows that ... and she wants to lessen its impact. "After showering ... that there needed to be a way to maintain ... use and producible in design variations, the End Scentuous ... throughout the day. It avoids bad odors, as well ...
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... Will Feature Nearly 100 Exhibits, Forums on Health Care ... Health Screenings and Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ... largest advocacy organization for people age 50+, today announced ... event to San Antonio on May 15-16. ...
... But it,s unlikely these factors cause the neurological condition, experts ... older mothers and children who have breech deliveries are almost ... researchers report. , The findings confirm those of other studies ... genetic base, researchers say. , "A child with breech ...
... surgeons can agree! There is often disagreement between ... the proper therapy for coronary artery disease (CAD)and ... edition of Deutsches rzteblatt International , an ... cardiac surgeons provides answers to the question of ...
... to attend TCT 2009 (Transcatheter Cardiovascular Therapeutics), the ... TCT gathers leading medical researchers and clinicians from ... latest developments in the field of interventional cardiology ... TCT brings state-of-the-art techniques and training to interventional ...
... National Infant Immunization Week is April 25 - May ... To kick off National Infant Immunization Week, ... for all parents to fully immunize their children against ... preventable diseases such as whooping cough, meningitis and measles ...
... IAC for Electronic ClaimsJACKSONVILLE, Fla., April 27 ... today announced that Insurers Administrative Corporation (IAC) has ... compliant electronic claims. As an Availity client, health ... Availity(R) Health Information Network free of charge.(Logo: ...
Cached Medicine News:Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Autism Tied to Older Moms, Breech Birth 2Health News:Autism Tied to Older Moms, Breech Birth 3Health News:Media registration now open for TCT 2009 2Health News:Pennsylvania Secretary of Health Reminds All Parents to 'Be Wise, Immunize Your Children' 2Health News:Insurers Administrative Corporation Joins the Availity Network 2
Wright-Giemsa Stain Solutions...
... For fast, single-solution staining, Hema-Quik ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
... for staining of peripheral blood smears ... stain formulations still in use today. ... of Giemsa stain, although eosinophillic granules ... granules and nuclear chromatin stain a ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: